Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Comment by Steveminon Feb 05, 2021 7:21pm
171 Views
Post# 32491070

RE:RE:RE:Absolute joke!!

RE:RE:RE:Absolute joke!!It absolutley boggles my mind that anyone would be ok with todays private placement.

- Inmed was not in a pinch for cash - they just raised $8M in Nov.
- The sp literally closed at $4.19 four days ago - how is this capitalizing on price appreciation?
- How does this justify an immediate 15% dilution (and further dilution when warrants are         exercised)
- If commercialization was eminent (as they stated it was), why not wait til then to capitalize on a big sp appreciation

So not only did Adams do a reverse split, he then diluted with the IPO (which was a bad deal) then diuted further AT A LOWER SP when there was no eminent need for cash.
Does this seem like sound leadership?

Honestly, Adams has to be in love with their current shareholders because you guys find a silver lining to everything he does. Someone on the FB page actually said "do you think they'll use the money to buy Baymedica"? I've seen alot of wacky things posted, but that one actually might take the cake. 
I really do wish you all good luck but boy oh boy.......

<< Previous
Bullboard Posts
Next >>